AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02531737
Drug: vargatef®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle
Trial: NCT00265200
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3.0-4.0 mg by IV (in the vein), once a month for 6 months
Trial: NCT02455440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03808844
Drug: HSK3486
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose of 0.4 mg/kg followed by 0.2 mg/kg if needed.
Trial: NCT00621244
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00508924
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03709914
Drug: ZTI-01 100 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZTI-01 intravenous (IV)
Trial: NCT03709914
Drug: ZTI-01 75 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZTI-01 intravenous (IV)
Trial: NCT02504606
Drug: Besylsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipin besylate 6.944mg+Losartan K 100mg
Trial: NCT02504606
Drug: Amosartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipin besylate 7.841mg+Losartan K 100mg
Trial: NCT03596905
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally daily for 4 weeks
Trial: NCT01935674
Drug: Continue Ritonavir-boosted PI+Rosuvastatin
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants).
Trial: NCT00869258
Drug: Gemcitabine, docetaxel, and capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1-14: Capecitabine 1500 mg/m2/day (+/- 2days) Day 4 and 11: Gemcitabine 750 mg/m2/day (+/- 2days) Day 4 and 11: Docetaxel 30 mg/m2/day (+/- 2 days) Two week treatment regimen is followed by one week off, repeated for a total of 3 cycles
Trial: NCT00636207
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dry powder inhaler
Trial: NCT00190619
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01551485
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pacebo tablet, blinded given on the first night after surgery
Trial: NCT00952588
Drug: AZD1152
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg, iv, 7 day infusion
Trial: NCT00413257
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bolus NaCl during 10 min at the end of surgery and during postoperative H48
Trial: NCT04496362
Drug: subcutaneous heparin anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The primary objective of this study is to evaluate the safety and efficacy of subcutaneous heparin anticoagulation compared to the standard of care systemic intravenous anticoagulation during veno-venous extracorporeal membrane oxygenation for respiratory failure. Subjects will be prospectively randomized in 1:1 ratio to subcutaneous heparin anticoagulation or systemic intravenous anticoagulation and followed until 1 week after discontinuation from ECMO support.
Trial: NCT03842488
Drug: Experimental: RAL QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription of 2x RAL 600mg (1200MG) once daily
Trial: NCT03842488
Drug: Active comparator: DRV/cb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription of DARUNAVIR/COBICISTAT 800 Mg-150 Mg once daily
Trial: NCT02785185
Drug: IDP-122 Vehicle Lotion
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle
Trial: NCT02785185
Drug: IDP-122 Vehicle Cream
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle
Trial: NCT02785185
Drug: IDP-122 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotion
Trial: NCT02139280
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mechanism of action: Cyclophosphamide is a pro drug that requires activation. Following hepatic and cellular activation, phosphoramide mustard and acrolein are formed. Phosphoramide mustard is the alkylating agent that demonstrates cytotoxic effects. Acrolein binds to proteins but does not contribute to the anti-tumor effects.
Trial: NCT02737371
Drug: Placebo dose level A oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo adverse events days 1-10
Trial: NCT02737371
Drug: F901318 Dose level B oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F901318 adverse events days 1-10
Trial: NCT02737371
Drug: Placebo dose level B oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo adverse events days 1-10
Trial: NCT02737371
Drug: F901318 Dose level C oral
RxNorm normalized name: C-Time Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F901318 adverse events days 1-10
Trial: NCT02737371
Drug: Placebo Dose level C oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo adverse events days 1-10
Trial: NCT01393665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03052634
Drug: RC48-ADC 1.5 mg/kg (HER2 Positive)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 1.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
Trial: NCT03052634
Drug: RC48-ADC 2.5 mg/kg (HER2 Positive)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
Trial: NCT03052634
Drug: RC48-ADC 2.0 mg/kg (HER2 Low Expression)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 advanced breast cancer participants with HER2 Low Expression will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
Trial: NCT01119924
Drug: Smilon®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
Trial: NCT01119924
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
Trial: NCT01599117
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
Trial: NCT00833040
Drug: Sublingual sufentanil NanoTabs™ and placebo NanoTabs™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the Titration Phase, patients titrated to the dose of sufentanil that provided adequate pain relief without intolerable side effects. Dosages were 20, 30, 40, 60 and 80 mcg. During the Double Blind Phase, patients were randomized to one of six sequences and took 7 doses of sufentanil (dosage determined in the titration phase, and 3 doses of placebo.
Trial: NCT03544736
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT04488601
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT01047241
Drug: Intranasal sufentanil/ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray sufentanil+ketamine, 0,5 microg/kg sufentanil+0,5 mg/kg ketamine, single dose
Trial: NCT02087241
Drug: AZD1775
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies
Trial: NCT01088659
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally daily, 96 weeks
Trial: NCT02897011
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01161186
Drug: nab-paclitaxel, gemcitabine, capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: {nab-paclitaxel: Intravenous, 100 to 150 mg/m2 over 30 minutes once per cycle.} {gemcitabine: Intravenous, 750 to 1000 mg/m2 at 10mg/m2/minute once per cycle.} {capecitabine: oral, 500 to 1000 mg/m2 b.i.d. 7 days per cycle}
Trial: NCT01487694
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo without active ingredient 1 tab daily for 12 weeks
Trial: NCT02779634
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill three times daily
Trial: NCT00182169
Drug: Human recombinant growth hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00788034
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily
Trial: NCT02012569
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01102231
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)
Trial: NCT02197975
Drug: PT010 Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
Trial: NCT02197975
Drug: PT010 Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PT010 Dose 2; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
Trial: NCT02197975
Drug: Placebo MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo MDI. Administered as 2 inhalations
Trial: NCT02483715
Drug: High-dose dual therapy (rabeprazole, amoxicillin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)
Trial: NCT01563406
Drug: 3.15% chlorhexidine/70% isopropyl alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.15% chlorhexidine gluconate in 70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters during half of the study period.
Trial: NCT00648492
Drug: Glucophage® XR 500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg, single dose fed
Trial: NCT00454714
Drug: Single dose placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of a single dose placebo
Trial: NCT00285896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous subcutaneous placebo infusion at a dose of 4.8 pmol/kg/min for 51 hours
Trial: NCT00888693
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Arm Description for details.
Trial: NCT02034773
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered once daily for up to 28 days
Trial: NCT00572663
Drug: ACC (N-acetylcysteine) 1200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (ACC) 1200 mg In the 8-weeks run-in period angiotensin converting enzyme inhibitors and/or angiotensin II subtype 1 receptor antagonists were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 1200 mg N-acetylcysteine in two active treatment periods lasting 8 weeks each
Trial: NCT01095939
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets; oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
Trial: NCT01466608
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral administration of rosuvastatin 20 mg once daily for 21 days.
Trial: NCT01012037
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient to receive placebo tablet(s) matching linagliptin
Trial: NCT02760615
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine tablets
Trial: NCT00669890
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conditioning Regimen
Trial: NCT00669890
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GVHD Prophylaxis
Trial: NCT00830544
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy
Trial: NCT02388581
Drug: Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-H. pylori Therapy
Trial: NCT02960217
Drug: UX007
RxNorm normalized name: UX007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liquid for oral (PO) administration
Trial: NCT02960217
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liquid safflower oil for PO administration
Trial: NCT02650544
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in placebo arm will be orally administered placebo; along with palliative chemotherapy.
Trial: NCT01501604
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 MG PO QD in cycles of 28 days
Trial: NCT01356160
Drug: GS-9451 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match GS-9451 QD
Trial: NCT00549692
Drug: Omega-3 fatty acid ethylester90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form :1g soft capsule Dosage : two capsules, twice a day.
Trial: NCT03576508
Drug: CNTX-4975-05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg (2mL) IA injection
Trial: NCT00701285
Drug: pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pravastatin 10mg once daily
Trial: NCT01188369
Drug: placebo drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion, colour identical to levosimendan
Trial: NCT04611932
Drug: CKD-330 Tab. and D090 Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1T
Trial: NCT03473236
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled placebo
Trial: NCT04611932
Drug: CKD-333 Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1T
Trial: NCT00626444
Drug: Intravenous vitamin C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 100 gms of intravenous vitamin C, three times per week for 10 weeks.
Trial: NCT03196882
Drug: 40mg/day of iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrimanitol ovalbumin granulated. Powder for oral solution. The doses of 40 mg per day of elemental iron correspond to 300 mg ferrimanitol ovoalbumin
Trial: NCT03196882
Drug: 80mg/day of iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrimanitol ovalbumin granulated. Powder for oral solution The doses of 80 mg per day of elemental iron correspond to 600 mg ferrimanitol ovoalbumin.
Trial: NCT01369069
Drug: IV insulin to maintain target glucose concentration of 80-130 mg/dL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention is to keep glucose concentration 80-130 mg/dL for up to 72 hours after randomization. IV insulin drip will be used to maintain glucose target.
Trial: NCT04101227
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to AD04 (ondansetron), orally (p.o.) twice a day (BID)
Trial: NCT03233633
Drug: Medical Marijuana
RxNorm normalized name: Picea mariana resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule, high ratio CBD:THC
Trial: NCT03351699
Drug: MK-4250
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-4250 tablets for oral administration
Trial: NCT00689312
Drug: Enfalyte
RxNorm normalized name: Electrolytes Oral Solution [ENFAMIL ENFALYTE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will receive one 250 ml dose.
Trial: NCT00689312
Drug: Pediatric Electrolyte
RxNorm normalized name: Pediatric Electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will receive one 250 ml dose.
Trial: NCT00689312
Drug: Pedialyte
RxNorm normalized name: Pedialyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will receive one 250 ml dose.
Trial: NCT00190606
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03588715
Drug: 3BNC117 + 10-1074
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broadly Neutralizing Antibodies - Sequential, separate IV infusions of 3NBC117 + 10-1074.
Trial: NCT03071263
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 packets/day starting dose, administered orally
Trial: NCT03071263
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg tablet/day starting dose, administered orally
Trial: NCT03071081
Drug: TOP1288
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TOP1288
Trial: NCT03034486
Drug: D930, D565
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1: D565 administered 1 time for one day/ Period 2: D930 administered 3 time per day for 9 days/ Period 3: D565(1 time per day) with D930(3 time per day) administered for 9days
Trial: NCT03071081
Drug: Placebo to TOP1288
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo to TOP1288
Trial: NCT04211740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is supplied as granules and take orally once a week.
Trial: NCT02735044
Drug: Background therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast-acting mealtime insulin analogs
Trial: NCT00864123
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This intervention involves taking a placebo pill(s) that matches the d-cycloserine capsules in size, shape, weight, and taste. Placebo contains an no active medication.
Trial: NCT01863823
Drug: Amoxicillin and Tetracyclines
RxNorm normalized name: tetracycline and nystatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 202 symptomatic and 148 asymptomatic individuals were recruited and tested using Saliva H. pylori antigen tests (HPS), H. pylori flagellin (HPF), the urea breathe test (UBT) and the polymerase chain reaction (PCR) test. Test subjects also received various treatments.
Trial: NCT03841110
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lympho-conditioning agent
Trial: NCT04228263
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg
Trial: NCT03289208
Drug: MCI-186
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of edaravone will be administered intravenously over 60 minutes.
Trial: NCT01601535
Drug: MLN8237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.
Trial: NCT03084796
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Control
Trial: NCT00647296
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 2 tablets taken orally twice daily
Trial: NCT00062712
Drug: Allogeneic Bone Marrow, Anti-Thymocyte Globulin (Sangstat) & Sirolimus (Wyeth-Ay
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00358475
Drug: GW685698
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04520607
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthcare professional-administered intra-articular injection of vehicle.
Trial: NCT02997501
Drug: AZD9291 Dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
Trial: NCT02214550
Drug: cyclic microgestin 1/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic OC Use - Participants will ingest pills containing active hormones for 21 days followed by 7 days of no pills, and then the cycle will repeat
Trial: NCT02214550
Drug: continuous microgestin 1/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous OC use - Pills containing hormones will be taken every day for 1 year
Trial: NCT04711213
Drug: Placebo Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suspension dose 1
Trial: NCT04711213
Drug: Placebo Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suspension dose 2
Trial: NCT04918706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be an equivalent volume NaCl 0,9% and DMSO 5%